tradmap

CUE Earnings Cue Biopharma, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$1 -$1 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $14M $27M 2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$53M -$27M $0 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$28 -$14 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $11M $22M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$153M -$76M $2M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–20 of 20
Q2 20262026-06-30-28.392026-08-1410-Q
Q1 20262026-03-31-1.082026-05-1410-Q
FY 20252025-12-31-0.282026-03-1610-K
Q3 20252025-09-30-0.312025-11-1210-Q
Q2 20262025-06-30-7.332026-08-1410-Q
Q1 20262025-03-31-4.952026-05-1410-Q
FY 20252024-12-31-0.722026-03-1610-K
Q3 20252024-09-30-0.622025-11-1210-Q
Q2 20252024-06-30-0.452025-08-1210-Q
Q1 20252024-03-31-0.252025-05-1210-Q
FY 20242023-12-31-1.112025-03-3110-K
Q3 20242023-09-30-0.822024-11-1410-Q
Q2 20242023-06-30-0.592024-08-1410-Q
Q1 20242023-03-31-0.292024-05-0910-Q
FY 20232022-12-31-1.492024-03-2810-K
Q3 20232022-09-30-1.112023-11-0310-Q
Q2 20232022-06-30-0.812023-08-0810-Q
Q1 20232022-03-31-0.442023-05-0910-Q
FY 20222021-12-31-1.412023-03-2110-K
Q3 20222021-09-30-1.162022-11-1410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.